BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1420 related articles for article (PubMed ID: 30429043)

  • 1. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 4. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
    Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
    Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in
    Tian X; Li Y; Huang Q; Zeng H; Wei Q; Tian P
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.